Literature DB >> 20052713

Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.

Robert Cavaliere1, Gina Petroni, Maria B Lopes, David Schiff.   

Abstract

BACKGROUND: Primary central nervous system (CNS) post-transplantation lymphoproliferative disorder (PCNS-PTLD) is a rare complication of solid organ transplantation. The objectives of this study were to define the clinical, radiologic, and pathologic features of this disease and to explore the impact of treatment on patient outcomes.
METHODS: The authors reviewed the databases of participating institutions of the International Primary CNS Lymphoma Collaborative Group for cases of PCNS-PTLD. Thirty-four patients who had pathologically confirmed PCNS-PTLD without evidence of systemic PTLD were investigated retrospectively.
RESULTS: The median time from transplantation to diagnosis of PCNS-PTLD was 4.4 years. Disease usually was multifocal and involved any location of the brain but was most common in the cerebral hemispheres, usually in the subcortical white matter or basal ganglia. Radiographically, all lesions enhanced either homogenously or in a ring-enhancing pattern. Cerebral biopsy was required to establish diagnosis in most patients. Most patients had monomorphic, Epstein-Barr virus (EBV)-positive disease of B-cell origin. Response rates were high regardless of treatment type, and the median survival was 47 months. Age was the only factor predictive of survival.
CONCLUSIONS: The current study demonstrated that PCNS-PTLD is typically an EBV-induced B-cell lymphoma that is responsive to treatment with favorable survival in many patients. An aggressive approach to tissue confirmation of diagnosis and treatment with chemotherapy or radiotherapy should be strongly considered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20052713      PMCID: PMC4113953          DOI: 10.1002/cncr.24834

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?

Authors:  T W Ruhstaller; U Amsler; T Cerny
Journal:  Ann Oncol       Date:  2000-03       Impact factor: 32.976

2.  Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma.

Authors:  Daniel J Skiest; Craig Crosby
Journal:  AIDS       Date:  2003-08-15       Impact factor: 4.177

3.  Rituximab dose-escalation trial in chronic lymphocytic leukemia.

Authors:  S M O'Brien; H Kantarjian; D A Thomas; F J Giles; E J Freireich; J Cortes; S Lerner; M J Keating
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

Review 4.  Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies.

Authors:  D V Faller; S J Mentzer; S P Perrine
Journal:  Curr Opin Oncol       Date:  2001-09       Impact factor: 3.645

5.  Posttransplant primary CNS lymphoma.

Authors:  T G Phan; B P O'Neill; P J Kurtin
Journal:  Neuro Oncol       Date:  2000-10       Impact factor: 12.300

6.  Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation?

Authors:  D Schiff; B O'Neill; E Wijdicks; J H Antin; P Y Wen
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

7.  Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma.

Authors:  Sameek Roychowdhury; Ruoqi Peng; Robert A Baiocchi; Darshna Bhatt; Srinivas Vourganti; John Grecula; Nilendu Gupta; Charles F Eisenbeis; Gerard J Nuovo; Weilian Yang; Petra Schmalbrock; Amy Ferketich; Melvin Moeschberger; Pierluigi Porcu; Rolf F Barth; Michael A Caligiuri
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

8.  Primary brain lymphomas after kidney transplantation: presentation and outcome.

Authors:  Renaud Snanoudj; Antoine Durrbach; Véronique Leblond; Sophie Caillard; Bruno Hurault De Ligny; Christian Noel; Eric Rondeau; Bruno Moulin; Marie-France Mamzer-Bruneel; Catherine Lacroix; Bernard Charpentier
Journal:  Transplantation       Date:  2003-09-27       Impact factor: 4.939

9.  Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children.

Authors:  Mary M Taj; Boo Messahel; Julie Mycroft; Kathy Pritchard-Jones; Alistair Baker; Susan Height; Nedim Hadzic; C Ross Pinkerton
Journal:  Br J Haematol       Date:  2008-01       Impact factor: 6.998

10.  Primary central nervous system posttransplant lymphoproliferative disorders.

Authors:  Amilcar A Castellano-Sanchez; Shiyong Li; Jiang Qian; Anand Lagoo; Edward Weir; Daniel J Brat
Journal:  Am J Clin Pathol       Date:  2004-02       Impact factor: 2.493

View more
  50 in total

1.  Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study.

Authors:  M Wu; J Sun; Y Zhang; F Huang; H Zhou; Z Fan; L Xuan; G Yu; X Guo; M Dai; R Feng; Q Liu
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

Review 2.  Neurologic complications after liver transplantation.

Authors:  Saša A Zivković
Journal:  World J Hepatol       Date:  2013-08-27

3.  High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder.

Authors:  A Patrick; A Wee; A Hedderman; D Wilson; J Weiss; M Govani
Journal:  J Neurooncol       Date:  2010-09-26       Impact factor: 4.130

4.  Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.

Authors:  Heiner Zimmermann; Mirko Nitsche; Christiane Pott; Petra Reinke; Nina Babel; Robert M Hermann; Ingeborg A Hauser; Dennis Hahn; Matthias Ritgen; Claudia Pietschmann; Wolfram Klapper; Ioannis Anagnostopoulos; Ralf U Trappe
Journal:  Ann Hematol       Date:  2021-05-11       Impact factor: 3.673

Review 5.  Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.

Authors:  Ajay Major; Manali Kamdar
Journal:  Curr Treat Options Oncol       Date:  2018-05-24

Review 6.  The neurology of solid organ transplantation.

Authors:  J David Avila; Saša Živković
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

7.  Neurological symptoms in a post-transplant patient: a cautionary tale.

Authors:  Suresh Kumar Chhetri; Rejith Dayanandan; Joseph Jacob; Hemant Sonwalkar; Aimun Ahmed; Varadarajan Kumar; Hedley C A Emsley
Journal:  J Neurol       Date:  2012-10-27       Impact factor: 4.849

Review 8.  Conservative management of post-transplant central nervous system lymphoma.

Authors:  Shahul H Valavoor; Zubair Ashraf; Rawan Narwal; Shobha Ratnam
Journal:  Int Urol Nephrol       Date:  2012-04-03       Impact factor: 2.370

9.  Post-transplant primary central nervous system lymphoma after Epstein-Barr virus cerebellitis.

Authors:  Cristina Valencia-Sanchez; Kristen K Steenerson; Katalin Kelemen; Robert Orenstein; Shimon Kusne; Marie F Grill
Journal:  J Neurovirol       Date:  2019-01-03       Impact factor: 2.643

10.  Primary brain lymphomas after kidney transplantation: an under-recognized problem?

Authors:  Nuria Sola-Valls; Néstor Yesid Rodríguez C; Carola Arcal; Carlos Duran; Federico Oppenheimer; Teresa Ribalta; Armando Lopez-Guillermo; Josep Marí Campistol; Francesc Graus; Fritz Diekmann
Journal:  J Nephrol       Date:  2014-01-28       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.